BCL2 and lymphoproliferative syndrome: Our findings underline the probable pathogenic role of BCL2 in LyP and the potential therapeutic efficacy of venetoclax for the treatment of this primary cutaneous CD30<sup>+</sup> lymphoproliferative disorder, especially in the setting of severe and refractory disease.